Pfizer Limited has entered into an exclusive Supply and Marketing Agreement with Cipla Limited for the marketing and distribution of four of its brands: Corex Dx, Corex LS, Dolonex, and Neksium. This agreement is for an initial period of 5 years and is effective domestically within India. Under the terms of the agreement, Cipla will exclusively market, distribute, and sell these brands. Pfizer will continue to manufacture, source, and supply the medicines to Cipla for the Indian market. This partnership aims to leverage Cipla's extensive customer understanding, distribution reach, and network to ensure wider availability of these medicines across India. The agreement does not involve any upfront consideration paid or received. However, it will entail a reduction in Pfizer Limited's field force, and the company will support impacted colleagues in their career transition. The financial impact of this reduction will be disclosed in the ensuing financial results. Both companies expressed optimism about the partnership, highlighting its potential to meet patient needs and advance healthcare outcomes.